Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the third quarter ended September 30, 2008.

"We continue to make rapid progress in both of our hepatitis C development programs," said Steve Worland Ph.D., President and CEO of Anadys. "We completed our first clinical study of ANA598 in healthy volunteers and have now completed the healthy volunteer portion of our ongoing ANA773 study. For both programs, we are very encouraged by the data and look forward to initiating patient dosing this quarter."

Financial Results

As of September 30, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $34.4 million.

During the third quarter of 2008 the Company had no revenue, compared to $21.5 million for the same quarter of 2007. The revenue in the third quarter of 2007 was primarily derived from the recognition of previously deferred revenue associated with an upfront payment and a milestone payment under a prior collaboration.

Research and development expenses were $7.6 million for the third quarter of 2008 and 2007. During the third quarter of 2008, cost savings derived from Anadys' completed strategic restructuring and associated termination of prior development programs were offset by a significant increase in ANA598 development costs.

General and administrative expenses were $2.1 million for the third quarter of 2008, compared to $2.4 million for the third quarter of 2007. The $0.3 million decrease primarily resulted from cost savi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... A long-term retrospective study of breast ... via interstitial brachytherapy suggests that women younger than ... be suitable to receive the treatment. Current American ... patients in the "unsuitable" category for APBI. In ... Beaumont Health System,s Peter Y. Chen , ...
(Date:9/17/2014)... PRINCETON, N.J. , Sept. 17, 2014 /PRNewswire/ ... developing targeted therapeutic devices to address infectious disease, cancer ... Sciences, Inc. (ESI), disclosed today that each company will ... Summit. On September 18 th , ... presentation entitled: "Exosomes: A Multiplexed Platform for Clinical Management." ...
(Date:9/17/2014)... JH Technologies announces the grand opening ... JH Technologies, a leader in sales and support of ... partnership with Leica Microsystems into the Southern California market. ... will be featured at the grand opening slated for ... is located within the JH Technologies office’s at 18025 ...
(Date:9/17/2014)... 2014 Intarcia Therapeutics, Inc. today ... study of the cost and predictability of non-adherence in ... Annual Meeting of the European Association for the Study ... Christian Frois , Ph.D., of Analysis Group, Inc. presented ... Intarcia-sponsored, retrospective studies to characterize the prevalence of non-adherence ...
Breaking Biology Technology:Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5
... to Accelerate Workflow, CHICAGO, Nov. 27 ... the MAMMOMAT(R) Novation S, a new,digital mammography ... at the 93rd Scientific Assembly and Annual ... (RSNA) from Nov. 25 to 30 at,McCormick ...
... of Health, Labor and Welfare (MHLW), for the revolutionary ... ... the blood, IRVINE, Calif., Nov. 27 Masimo, the ... today announced approval of the Masimo Rad-57 Pulse CO-Oximeter,bringing the ...
... UCLA,s California NanoSystems Institute, the David Geffen School of ... have modeled the structure of the largest cellular particle ... drug delivery. , The research study, ... as a drug-therapy vehicle, appears in the Nov. 27 ...
Cached Biology Technology:Siemens Unveils New Digital Mammography System for Optimized Screening 2Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 2Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 3Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 4Researchers outline structure of largest nonvirus particle ever crystallized 2
(Date:9/17/2014)... a new crime unit designed to fight food fraud ... horse meat being passed off as beef scientists ... adulteration. They describe their approach, which represents a vast ... Agricultural and Food Chemistry . , Hans-Ulrich Humpf and ... economic problem. But they also say that adding, for ...
(Date:9/16/2014)... for Children,s Environmental Health at the Mailman School of ... between childhood asthma and prenatal exposure to two phthalates ... appear online in the journal Environmental Health Perspectives ... pregnancy to higher levels of the chemicals, butylbenzyl phthalate ... and 78 percent increase in risk of developing asthma ...
(Date:9/16/2014)... September, 2014)More than $100 trillion in cumulative public ... carbon dioxide (CO2)a 40 percent reduction of urban ... the world expands public transportation, walking and cycling ... by the University of California, Davis, and the ... , Further, an estimated 1.4 million early deaths ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5
... Wireless ... for Emergency Responders, WALL, N.J., Oct. 15 BIO-key ... and wireless public safety solutions, today announced that,it will be ... Chiefs of Police (IACP) Conference and,Exposition, October 15-17 at the ...
... (AD) is a progressive neurodegenerative disorder characterized by ... amyloid plaques and neurofibrillary tangles. Neuronal and synaptic ... occur in specific brain areas involved in memory ... cerebral deposition of A" plays a seminal role ...
... to ramp up testosterone production appears to drive male ... comes with an evolutionary cost. Big fluctuations in testosterone ... their own young, scientists have learned. In ... Indiana University Bloomington, University of Virginia and University of ...
Cached Biology News:BIO-key International Showcasing Innovative Public Safety Solutions at 2007 IACP Conference 2BIO-key International Showcasing Innovative Public Safety Solutions at 2007 IACP Conference 3Paradigm shift in Alzheimers's research: new treatments 2Paradigm shift in Alzheimers's research: new treatments 3Paradigm shift in Alzheimers's research: new treatments 4Testosterone turns male juncos into blustery hunks -- and bad dads 2Testosterone turns male juncos into blustery hunks -- and bad dads 3
Peptide-affinity Purified Polyclonal Antibody to Purinergic Receptor P2Y12...
Purified anti-PXR...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Purified anti-DNA-PKcs Phosphorylated (Thr2609)...
Biology Products: